Abstract
We report 18F-flutemetamol PET/CT finding in an 88-year-old man with cognitive impairment and transthyretin amyloid cardiomyopathy. Early phase PET/CT images showed significantly increased myocardial uptake, but there was no myocardial uptake in delayed phase PET/CT images. A dual-time-point amyloid PET/CT imaging may be helpful to diagnose and differentiate subtypes of amyloid cardiomyopathy in patients with suspected cardiac amyloidosis.
| Original language | English |
|---|---|
| Pages (from-to) | 1074-1076 |
| Number of pages | 3 |
| Journal | Clinical Nuclear Medicine |
| Volume | 47 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1 Dec 2022 |
Bibliographical note
Publisher Copyright:© Wolters Kluwer Health, Inc. All rights reserved.
Keywords
- ATTR
- F-flutemetamol
- amyloid PET
- cardiac amyloidosis
Fingerprint
Dive into the research topics of '18F-Flutemetamol PET/CT for Transthyretin Amyloid Cardiomyopathy: Timing Matters'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver